Soykan ÖZKOÇ, Hakan AY, Seray TÖZ, Gürkan MERT, Kemal ŞİMŞEK, Mehmet TANYÜKSEL, Özgür KORU

In vitro efficacy of hyperbaric oxygen therapy against Leishmania tropica promastigotes and amastigotes

Aim: To assess the efficiency of hyperbaric oxygen (HBO) therapy on L. tropica, which is the major causative agent of cutaneous leishmaniasis in Turkey. Materials and methods: The effects of HBO on Leishmania tropica promastigote and amastigote forms were studied at a pressure of 2.5 atmosphere absolute (ata). We examined the cytotoxic effect of HBO on promastigotes using the trypan blue exclusion test and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye-reduction assay. To investigate the effects of HBO treatment on the growth of the promastigotes, HBO-treated and non-HBO-treated cell culture flasks were incubated at 26 °C for 3 days, while the effects of HBO on L. tropica amastigotes were detected using the acridine orange staining method. Results: We observed that the cytotoxic effect emerged after 2 h and reached a maximum at 6 h with both methods. The number of live promastigotes was monitored for 24 h after treatment and there was a slight elevation at 2 h of treatment, but significant suppression was seen after 4 and 6 h of treatment (P < 0.001). We detected that the effect of HBO on L. tropica amastigote forms increased by 3.3%, 17.2%, and 38.5% at 2, 4, and 6 h, respectively. Conclusion: The results presented here indicate that HBO treatment could be used as supportive therapy in association with chemotherapeutic agents against L. tropica infection.

Anahtar Kelimeler:

Key words: Hyperbaric oxygen, Leishmania tropica, cytotoxicity

In vitro efficacy of hyperbaric oxygen therapy against Leishmania tropica promastigotes and amastigotes

Keywords:

Key words: Hyperbaric oxygen, Leishmania tropica, cytotoxicity,

PDF

___

Garcia LS. Diagnostic medical parasitology. 4th ed. Washington, DC: ASM Press; 2001. p.205-35. 2. Herwaldt BL. Leishmaniasis. Lancet 1999; 354: 1191-9.
Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27: 305-18. 4. John DT, Petri WA. Markell and Voge’s medical parasitology. 9th ed. St. Louis (MO): W.B. Saunders; 2006. p.127-39. 5. Pearson RD, Sousa AQ, Jeronimo SMB. Leishmania species: visceral (Kala-azar), cutaneous, and mucosal leishmaniasis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia (PA): Churchill Livingstone Press; 2000. p.2831-45.
David CV, Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatol Th er 2009; 22: 491-502. 7. Ozbel Y, Turgay N, Ozensoy S, Ozbilgin A, Alkan MZ, Ozcel MA et al. Epidemiology, diagnosis and control of leishmaniasis in the Mediterranean region. Ann Trop Med Parasitol 1995; 89: 89-93.
Akkafa F, Dilmec F, Alpua Z. Identifi cation of Leishmania parasites in clinical samples obtained from cutaneous leishmaniasis patients using PCR-RFLP technique in endemic region, Sanliurfa province, in Turkey. Parasitol Res 2008; 103: 583-6. 9. Ok ÜZ, Balçıoğlu İC, Taylan Özkan A, Özensoy S, Özbel Y. Leishmaniasis in Turkey. Acta Trop 2002; 84: 43-8.
Tanyuksel M, Bas AL, Araz E, Aybay C. Determination of intracellular effi cacies of azithromycin against Leishmania major infection in human neutrophils in vitro. Cell Biochem Funct 2003; 21: 93-6.
Singh N. Drug resistance mechanisms in
clinical isolates of Leishmania donovani. Indian J Med Res 2006; 123: 411-22.
Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004; 53: 158-66.
Gonzáles U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009; 15: CD004834.
Gradoni L, Soteriadou K, Louzir H, Dakkak A, Toz SO, Jaff e C et al. Drug regimens for visceral leishmaniasis in Mediterranean countries. Trop Med Int Health 2008; 13: 1272-6.
Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res 2006; 123: 399-410.
Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Mic Rev 2006; 19: 111-26.
Hink J, Jansen E. Are superoxide and/or hydrogen peroxide responsible for some benefi cial eff ects of hyperbaric therapy? Med Hypotheses 2001; 57: 764-9.
Park M. Eff ects of hyperbaric oxygen in infectious diseases: basic mechanisms. In: Kindwall E, Whelan H, editors. Hyperbaric medicine practice. 2nd ed. Flagstaff (AZ): Best Publishing Company; 2004. p.205-44.
Young MH, Engleberg NC, Mulla ZD, Aronoff DM. Th erapies for necrotising fasciitis. Expert Opin Biol Th er 2006; 6: 55-65.
Murray HW. Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. J Exp Med 1981; 153: 1302-15.
Murray HW, Nathan CF. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 1999; 189: 741-6.
Reiner NE, Kazura JW. Oxidant-mediated damage of Leishmania donavzni promastigotes. Infect Immun 1982; 36: 1023-7.
Arrais-Silva WW, Collhone MC, Ayres DC, de Souza Souto PC, Giorgio S. Eff ects of hyperbaric oxygen on Leishmania amazonensis promastigotes and amastigotes. Parasitol Int 2005; 54: 1-7.
Arrais-Silva WW, Pinto EF, Rossi-Bergmann B, Giorgio S. Hyperbaric oxygen therapy reduces the size of Leishmania amazonensis-induced soft tissue lesions in mice. Acta Trop 2006; 98: 130-6.
Muhvich KH, Anderson LH, Criswell DW, Mehm WJ. Hyperbaric hyperoxia enhances the lethal eff ects of amphotericin B in Leishmania braziliensis panamensis. Undersea Hyberb Med 1993; 20: 321-8.
Dutta A, Bandyopadhyay S, Mandal C, Chatterjee M. Development of a modifi ed MTT assay for screening antimonial resistant fi eld isolates of Indian visceral leishmaniasis. Parasitol Int 2005; 54: 119-22.
Channon JY, Roberts MB, Blackwell JM. A study of the diff erential respiratory burst activity elicited by promastigotes and amastigotes of Leishmania donovani in murine resident peritoneal macrophages. Immunol 1984; 53: 345-55.
Channon JY, Blackwell JM. A study of sensitivity of Leishmania donovani promastigotes and amastigotes to hydrogen peroxide. Parasitology 1985; 91: 197-206.
Miller MA, McGowan SE, Gantt KR, Champion M, Novick SL, Andersen KA et al. Inducible resistance to oxidant stress in the protozoan Leishmania chagasi. J Biol Chem 2000; 275: 33883-9.
Murray HW. Cell-mediated immune response in experimental visceral leishmaniasis. II: Oxygen-dependent killing of intracellular Leishmania donovani amastigotes. J Immunol 1982; 129: 351-7.
Das M, Mukherjee SB, Shaha C. Hydrogen peroxide induces apoptosis-like death in Leishmania donovani promastigotes. J Cell Sci 2001; 114: 2461-9.
Clark LA, Monn RE. Hyperbaric oxygen in the treatment of life-threatening soft -tissue infections. Respir Care Clin N Am 1999; 5: 203-19.